Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113954 | 0.84 | MAOB (0.40) | TSHRMAPK1L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL121487 | 0.84 | KDM4E (0.46) | TSHRMAPK1L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL9798371 | 0.80 | LTA4H (0.54) | TSHRMAPK1L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL841548 | 0.79 | CYP3A4 (0.46) | MAPK1L3MBTL1PPARGLMNAHSD17B10 | |
| SCHEMBL4506704 | 0.78 | PPARG (0.40) | KDM4EMAOBPPARGPPARACES2 | |
| SCHEMBL521971 | 0.78 | IDO1 (0.40) | TSHRIDO1CES2ALDH1A1 | |
| SCHEMBL5608697 | 0.77 | TSHR (0.48) | TSHRMAPK1L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL4214531 | 0.77 | TSHR (0.54) | TSHRMAPK1L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL167016 | 0.77 | L3MBTL1 (0.58) | TSHRMAPK1L3MBTL1KDM4EMAOB | |
| SCHEMBL11527555 | 0.77 | KIF11 (0.51) | TSHRMAPK1L3MBTL1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732574-A | Preparation of thianthrene-5, 5,10, 10-tetraoxide derivative and organic electroluminescent device based on thianthrene-5, 5,10, 10-tetraoxide derivative | 中国科学院理化技术研究所 | 2016-07-06 | — | — | CN | claimed |
| CN-105693608-A | 2, 2-dimethyl-1, 3-indene dione derivatives and organic electroluminescent devices based thereon | 中国科学院理化技术研究所 | 2016-06-22 | — | — | CN | claimed |
| CN-105220473-A | A kind of water-proof aagent and application thereof | HOPERISE TEXTILES CO LTD QUANZHOU | 2016-01-06 | — | — | CN | claimed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250179017-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| WO-2025110621-A1 | NOVEL OXAZOLE-BASED COMPOUND AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING INFLAMMATORY DISEASES COMPRISING SAME | 고려대학교 세종산학협력단 | 2025-05-30 | — | — | WO | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119874668-A | Main protease regulator and application thereof | 北京昌平实验室 | 2025-04-25 | — | — | CN | disclosed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000046184-A1 | N2-PHENYLAMIDINE DERIVATIVES | AVENTIS CROPSCIENCE GMBH (FR) | 2000-08-10 | — | — | WO | disclosed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0691966-B1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX INC (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5530005-A | THERAPY FOR SKIN DISORDERS, AIDS, IMMUNOSUPPRESION DISEASES | SYNTEX (U.S.A.) INC. (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5475003-A | Antiinflammatory agent, immunosuppressive, antiallergens, bronchodilators, analgens | SYNTEX (U.S.A.) INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179017-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | PTGER1, PTGER2, CNR2 | TSHR 489/4885MAPK1 1164/4885L3MBTL1 4743/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | TSHR 2806/4885MAPK1 1015/4885L3MBTL1 4726/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | TSHR 3560/4885MAPK1 1623/4885L3MBTL1 4484/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | TSHR 3432/4885MAPK1 3746/4885L3MBTL1 969/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | TSHR 3647/4885MAPK1 1105/4885L3MBTL1 816/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | TSHR 2669/4885MAPK1 2405/4885L3MBTL1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.